Acepodia's ACE723 Receives FDA Clearance to Start Phase 1 Trials
Acepodia, a clinical-stage biotechnology company based in California and Taiwan, has recently achieved a significant milestone with the clearance of their Investigational New Drug (IND) application for ACE723. This approval, granted by the U.S. Food and Drug Administration (FDA), allows Acepodia to initiate Phase 1 clinical trials for this innovative therapeutic approach, aimed at targeting unresectable or metastatic hepatocellular carcinoma (HCC), which is a predominant form of liver cancer
ACE723 is developed using Acepodia’s proprietary Antibody-Dual-Drugs Conjugation (AD2C) platform. This platform enables the creation of a dual-payload antibody-drug conjugate (ADC) specifically targeting the Glypican-3 (GPC3) antigen, which is commonly expressed in liver cancer cells. The use of a dual payload is designed to combat tumor heterogeneity and the intrinsic resistance often encountered with single payload therapies. By delivering two potent cytotoxic agents directly to the cancer cells, ACE723 may enhance therapeutic efficacy against HCC, which currently lacks sufficiently differentiated therapeutic options.
Sonny Hsiao, CEO of Acepodia, expressed optimism regarding the FDA clearance, stating, “This marks an important milestone for our AD2C platform, bringing our first candidate into clinical development. We are excited to evaluate ACE723's safety, pharmacokinetics, and preliminary anti-tumor activity in patients.”
HCC constitutes over 70% of liver cancer cases globally. Despite existing treatments, the prognosis for patients with unresectable or metastatic disease remains poor, revealing a substantial gap in effective therapies. The planned Phase 1 study will assess various factors, including safety, tolerability, and the potential anti-tumor effects of ACE723. This study will involve dose escalation to pinpoint the recommended doses for future trials and may include expansion cohorts to further investigate the drug's effects.
Furthermore, Acepodia's strategy includes seeking approval from China's National Medical Products Administration (NMPA) for the same IND application, highlighting the company’s commitment to a global approach towards developing ACE723.
Acepodia leverages advanced biochemical techniques rooted in Nobel Prize-winning research by Carolyn Bertozzi. Their platforms are tailored to generate therapies that align with the specific characteristics of various cancers and autoimmune diseases. Through their innovative approach towards antibody engineering and drug conjugation, Acepodia continues to work on a pipeline that not only addresses urgent therapeutic needs but aims to redefine treatment standards across multiple malignancies.
In summary, the FDA clearance for ACE723 positions Acepodia for crucial developments in cancer treatment, specifically targeting the challenges presented by hepatocellular carcinoma. As they embark on Phase 1 clinical trials, anticipation builds around the potential of this novel therapy to offer hope to patients facing this aggressive form of cancer. For further updates on this and other projects, interested parties can visit Acepodia’s official website.
ACE723 is developed using Acepodia’s proprietary Antibody-Dual-Drugs Conjugation (AD2C) platform. This platform enables the creation of a dual-payload antibody-drug conjugate (ADC) specifically targeting the Glypican-3 (GPC3) antigen, which is commonly expressed in liver cancer cells. The use of a dual payload is designed to combat tumor heterogeneity and the intrinsic resistance often encountered with single payload therapies. By delivering two potent cytotoxic agents directly to the cancer cells, ACE723 may enhance therapeutic efficacy against HCC, which currently lacks sufficiently differentiated therapeutic options.
Sonny Hsiao, CEO of Acepodia, expressed optimism regarding the FDA clearance, stating, “This marks an important milestone for our AD2C platform, bringing our first candidate into clinical development. We are excited to evaluate ACE723's safety, pharmacokinetics, and preliminary anti-tumor activity in patients.”
HCC constitutes over 70% of liver cancer cases globally. Despite existing treatments, the prognosis for patients with unresectable or metastatic disease remains poor, revealing a substantial gap in effective therapies. The planned Phase 1 study will assess various factors, including safety, tolerability, and the potential anti-tumor effects of ACE723. This study will involve dose escalation to pinpoint the recommended doses for future trials and may include expansion cohorts to further investigate the drug's effects.
Furthermore, Acepodia's strategy includes seeking approval from China's National Medical Products Administration (NMPA) for the same IND application, highlighting the company’s commitment to a global approach towards developing ACE723.
Acepodia leverages advanced biochemical techniques rooted in Nobel Prize-winning research by Carolyn Bertozzi. Their platforms are tailored to generate therapies that align with the specific characteristics of various cancers and autoimmune diseases. Through their innovative approach towards antibody engineering and drug conjugation, Acepodia continues to work on a pipeline that not only addresses urgent therapeutic needs but aims to redefine treatment standards across multiple malignancies.
In summary, the FDA clearance for ACE723 positions Acepodia for crucial developments in cancer treatment, specifically targeting the challenges presented by hepatocellular carcinoma. As they embark on Phase 1 clinical trials, anticipation builds around the potential of this novel therapy to offer hope to patients facing this aggressive form of cancer. For further updates on this and other projects, interested parties can visit Acepodia’s official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.